NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031240331

Registered date:11/09/2024

Pharmacokinetic study of HP-5120

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedhealthy adult males and females
Date of first enrollment15/10/2024
Target sample size112
Countries of recruitment
Study typeInterventional
Intervention(s)[Single ascending dose in healthy adult Japanese males and females] In Cohort 1, a single dose of HP-5120 Dose 1 or placebo will be administered. In Cohort 2, a single dose of HP-5120 Dose 2 or placebo will be administered. In Cohort 3-1, a single dose of HP-5120 Dose 4 or placebo will be administered. In Cohort 3-2, a single dose of HP-5120 Dose 3 or placebo will be administered. In Cohort 4, a single dose of HP-5120 Dose 5 or placebo will be administered. [Single-dose administration by sex in healthy adult Japanese males and females] In the male group, the maximum tolerated dose of HP-5120 in Dose 1 or 2 will be administered at a single dose. In the female group, the maximum tolerated dose of HP-5120 in Dose 1 or 2 will be administered at a single dose. [Multiple doses in healthy Japanese adult males and females] HP-5120 among Doses 1 to 5 that have been found to be tolerated will be administered for 14 days in repeated dose study.

Outcome(s)

Primary OutcomePharmacokinetics, Safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximum< 45age old
GenderBoth
Include criteria- Healthy adult Japanese males and females aged 18 or older and younger than 45 years - Subjects weighing 40 kg or more
Exclude criteria- Subjects with or with a history of serious cardiovascular, renal, hepatic, gastrointestinal, endocrine, neuropsychiatric, dermatological, metabolic, or immunological disease - Subjects who received any drug within 1 week prior to administration of the investigational product - Subjects who took any drug considered to affect drug metabolism within 4 weeks prior to administration of the investigational product

Related Information

Contact

Public contact
Name Contact for Clinical Trial Information Clinical Development Department
Address 2-4-1 Marunouchi, Chiyoda-ku, Tokyo Tokyo Japan 100-6330
Telephone +81-3-5293-1734
E-mail shikenjoho@hisamitsu.co.jp
Affiliation Hisamitsu Pharmaceutical Co., Inc.
Scientific contact
Name Yusuke Tanaka
Address 2-4-1 Marunouchi, Chiyoda-ku, Tokyo Tokyo Japan 100-6330
Telephone +81-3-5293-1734
E-mail shikenjoho@hisamitsu.co.jp
Affiliation Hisamitsu Pharmaceutical Co., Inc.